<p>Plus Therapeutics, Inc.（纳斯达克代码：PSTV - 获取免费报告）的股票目前被七家覆盖该公司的券商给予了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，四位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 7.25 美元。</p>
<p>获取 <strong>Plus Therapeutics</strong> 的提醒：</p>
<p>PSTV 最近成为多份分析师报告的主题。Ascendiant Capital Markets 在 11 月 21 日的研究报告中将 Plus Therapeutics 的目标价从 21.00 美元下调至 19.00 美元，并给予该公司 “买入” 评级。D Boral Capital 在 9 月 3 日的报告中将 Plus Therapeutics 的股票评级从 “持有” 上调至 “强烈买入”。Zacks Research 在 11 月 11 日的报告中将 Plus Therapeutics 的股票评级从 “强烈买入” 下调至 “持有”。D. Boral Capital 在 12 月 11 日的报告中重申了 “买入” 评级，并对 Plus Therapeutics 的股票设定了 5.00 美元的目标价。最后，HC Wainwright 在 11 月 26 日的研究报告中重申了 “买入” 评级，并对 Plus Therapeutics 的股票设定了 2.00 美元的目标价。</p>
<p><strong>获取我们关于 Plus Therapeutics 的最新研究报告</strong></p>
<h2>Plus Therapeutics 股票表现</h2>
<p>PSTV 周五开盘价为 0.57 美元。该公司的 50 日移动平均价格为 0.59 美元，200 日移动平均价格为 0.51 美元。该公司的市值为 7813 万美元，市盈率为-0.30，贝塔值为 0.82。Plus Therapeutics 的 52 周低点为 0.16 美元，52 周高点为 2.31 美元。</p>
<p>Plus Therapeutics（纳斯达克代码：PSTV - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为-0.04 美元，低于市场共识预期的-0.02 美元，差距为-0.02 美元。该公司在季度内的收入为 140 万美元，而分析师预期为 150 万美元。股票分析师预测 Plus Therapeutics 在当前年度的每股收益将为-2.3。</p>
<h2>对 Plus Therapeutics 的对冲基金看法</h2>
<p>机构投资者最近调整了对该公司的持股。Jane Street Group LLC 在第二季度购买了 Plus Therapeutics 的新股份，金额约为 41,000 美元。Susquehanna International Group LLP 在第三季度收购了 Plus Therapeutics 的新头寸，价值约为 46,000 美元。Scientech Research LLC 在第三季度购买了 Plus Therapeutics 的新股份，金额为 100,000 美元。最后，Altium Capital Management LLC 在第三季度购买了 Plus Therapeutics 的新股份，金额为 628,000 美元。机构投资者持有该公司 3.28% 的股票。</p>
<h2>关于 Plus Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Plus Therapeutics 是一家临床阶段的生物制药公司，专注于开发针对肿瘤的靶向放射治疗药物。其平台技术利用纳米脂质体和微球将治疗性放射性同位素直接输送到肿瘤部位。该公司的主要候选药物 90Y-HP-DO3A 正在进行复发性高等级胶质瘤的二期开发，而其基于铼的纳米脂质体项目正在研究扩散性内在脑干胶质瘤和脑转移。</p>
<p>该管线还包括针对骨转移、恶性胸腔积液和其他难治性实体肿瘤的研究治疗。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Plus Therapeutics</li>
<li>复利是如何计算的？</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>股票情绪分析：它是如何工作的</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>这只 ETF 在美联储降息后获得了重大顺风</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Plus Therapeutics 吗？</h2>
<p>在考虑 Plus Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Plus Therapeutics 并不在名单上。</p>
<p>虽然 Plus Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PSTV

<p>Plus Therapeutics, Inc.（纳斯达克代码：PSTV）获得了七家券商的平均 “适度买入” 评级。该股票有一个卖出评级、一个持有评级、四个买入评级和一个强买入评级。平均一年价格目标为 7.25 美元。最近的分析师行动包括 Ascendiant Capital Markets 将其价格目标下调至 19.00 美元，以及 D Boral Capital 将评级上调至 “强买入”。该公司专注于肿瘤学的靶向放射治疗，其主要候选药物正在进行第二阶段开发</p>

<p>Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.25.</p>
<div class="lb-trans"><p>Plus Therapeutics, Inc.（纳斯达克代码：PSTV - 获取免费报告）的股票目前被七家覆盖该公司的券商给予了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，四位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 7.25 美元。</p>
</div><p>Get <strong>Plus Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Plus Therapeutics</strong> 的提醒：</p>
</div><p>PSTV has been the subject of a number of recent analyst reports. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $21.00 to $19.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, September 3rd. Zacks Research lowered shares of Plus Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 11th. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $5.00 price target on shares of Plus Therapeutics in a report on Thursday, December 11th. Finally, HC Wainwright restated a &#34;buy&#34; rating and issued a $2.00 price objective on shares of Plus Therapeutics in a research report on Wednesday, November 26th.</p>
<div class="lb-trans"><p>PSTV 最近成为多份分析师报告的主题。Ascendiant Capital Markets 在 11 月 21 日的研究报告中将 Plus Therapeutics 的目标价从 21.00 美元下调至 19.00 美元，并给予该公司 “买入” 评级。D Boral Capital 在 9 月 3 日的报告中将 Plus Therapeutics 的股票评级从 “持有” 上调至 “强烈买入”。Zacks Research 在 11 月 11 日的报告中将 Plus Therapeutics 的股票评级从 “强烈买入” 下调至 “持有”。D. Boral Capital 在 12 月 11 日的报告中重申了 “买入” 评级，并对 Plus Therapeutics 的股票设定了 5.00 美元的目标价。最后，HC Wainwright 在 11 月 26 日的研究报告中重申了 “买入” 评级，并对 Plus Therapeutics 的股票设定了 2.00 美元的目标价。</p>
</div><p><strong>Get Our Latest Research Report on Plus Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Plus Therapeutics 的最新研究报告</strong></p>
</div><h2>Plus Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Plus Therapeutics 股票表现</h2>
</div><p>PSTV opened at $0.57 on Friday. The company has a fifty day moving average price of $0.59 and a two-hundred day moving average price of $0.51. The firm has a market capitalization of $78.13 million, a PE ratio of -0.30 and a beta of 0.82. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31.</p>
<div class="lb-trans"><p>PSTV 周五开盘价为 0.57 美元。该公司的 50 日移动平均价格为 0.59 美元，200 日移动平均价格为 0.51 美元。该公司的市值为 7813 万美元，市盈率为-0.30，贝塔值为 0.82。Plus Therapeutics 的 52 周低点为 0.16 美元，52 周高点为 2.31 美元。</p>
</div><p>Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. Equities analysts forecast that Plus Therapeutics will post -2.3 EPS for the current year.</p>
<div class="lb-trans"><p>Plus Therapeutics（纳斯达克代码：PSTV - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告每股收益（EPS）为-0.04 美元，低于市场共识预期的-0.02 美元，差距为-0.02 美元。该公司在季度内的收入为 140 万美元，而分析师预期为 150 万美元。股票分析师预测 Plus Therapeutics 在当前年度的每股收益将为-2.3。</p>
</div><h2>Hedge Funds Weigh In On Plus Therapeutics</h2>
<div class="lb-trans"><h2>对 Plus Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in Plus Therapeutics during the 2nd quarter worth approximately $41,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics in the third quarter valued at approximately $46,000. Scientech Research LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. Finally, Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth $628,000. Institutional investors own 3.28% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Jane Street Group LLC 在第二季度购买了 Plus Therapeutics 的新股份，金额约为 41,000 美元。Susquehanna International Group LLP 在第三季度收购了 Plus Therapeutics 的新头寸，价值约为 46,000 美元。Scientech Research LLC 在第三季度购买了 Plus Therapeutics 的新股份，金额为 100,000 美元。最后，Altium Capital Management LLC 在第三季度购买了 Plus Therapeutics 的新股份，金额为 628,000 美元。机构投资者持有该公司 3.28% 的股票。</p>
</div><h2>About Plus Therapeutics</h2>
<div class="lb-trans"><h2>关于 Plus Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company's lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.</p>
<div class="lb-trans"><p>Plus Therapeutics 是一家临床阶段的生物制药公司，专注于开发针对肿瘤的靶向放射治疗药物。其平台技术利用纳米脂质体和微球将治疗性放射性同位素直接输送到肿瘤部位。该公司的主要候选药物 90Y-HP-DO3A 正在进行复发性高等级胶质瘤的二期开发，而其基于铼的纳米脂质体项目正在研究扩散性内在脑干胶质瘤和脑转移。</p>
</div><p>The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.</p>
<div class="lb-trans"><p>该管线还包括针对骨转移、恶性胸腔积液和其他难治性实体肿瘤的研究治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Plus Therapeutics</li>
<li>How is Compound Interest Calculated?</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Plus Therapeutics</li>
<li>复利是如何计算的？</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>股票情绪分析：它是如何工作的</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>这只 ETF 在美联储降息后获得了重大顺风</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PSTV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Plus Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Plus Therapeutics 吗？</h2>
</div><p>Before you consider Plus Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Plus Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plus Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Plus Therapeutics 并不在名单上。</p>
</div><p>While Plus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Plus Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Plus Therapeutics, Inc. (NASDAQ:PSTV) 获得分析师的平均评级为 “适度买入”